PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

PepGen Inc. PEPG announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in Phase 2 clinical development.The company voluntarily discontinued the development of PGN-EDO51 and intends to wind down all Duchenne muscular dystrophy (DMD)-)-related research and development activities.The decision is based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study of PGN-EDO51 in DMD patients amenable to exon 51 skipping.In ...